Question

The drug Eliquis (apixaban) is used to help prevent blood clots in certain patients. In clinical trials, among 5924 patients treated with Eliquis, 153 developed the adverse reaction of nausea (based on data from Bristol-Myers Squibb Co.). Use a 0.08 significance level to test the claim that 3% of Eliquis users develop nausea. Does nausea appear to be a problematic adverse reaction?

Answer 1

To test the claim that 3% of Eliquis users develop nausea, we need to perform a one-proportion z-test. Based on the analysis, there is not sufficient evidence to claim that nausea is a problematic adverse reaction to Eliquis.

Step-by-step explanation:

To test the claim that 3% of Eliquis users develop nausea, we need to perform a hypothesis test. The null hypothesis (H0) is that the proportion of Eliquis users who develop nausea is 3%, and the alternative hypothesis (Ha) is that the proportion is not 3%. We can use a one-proportion z-test to analyze the data.

1. Step 1: Calculate the sample proportion: p = 153/5924 = 0.0259
2. Step 2: Calculate the test statistic: z = (p - P) / sqrt(P * (1 - P) / n), where P is the hypothesized population proportion (0.03), and n is the sample size (5924).
3. Step 3: Compare the test statistic to the critical value. If the test statistic falls within the critical region (which is determined based on the significance level), we reject the null hypothesis. Otherwise, we fail to reject the null hypothesis.
4. Step 4: Make a conclusion based on the test result.

In this case, the test statistic z = (-0.004968 - 0.03) / sqrt(0.03 * (1 - 0.03) / 5924) ≈ -1.350. Using a significance level of 0.08, the critical value is approximately ±1.405. Since -1.350 falls within this range, we fail to reject the null hypothesis. Therefore, there is not sufficient evidence to claim that nausea is a problematic adverse reaction to Eliquis.